Wall Street brokerages predict that Nevro Corp (NYSE:NVRO) will report earnings of ($0.34) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Nevro’s earnings, with estimates ranging from ($0.49) to ($0.17). Nevro posted earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 32%. The firm is expected to report its next quarterly earnings report on Monday, May 14th.
According to Zacks, analysts expect that Nevro will report full year earnings of ($0.76) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($0.25). For the next fiscal year, analysts expect that the business will report earnings of $0.01 per share, with EPS estimates ranging from ($0.48) to $0.52. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Nevro.
Nevro (NYSE:NVRO) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $97.96 million during the quarter, compared to analysts’ expectations of $96.87 million. Nevro had a negative net margin of 11.22% and a negative return on equity of 15.01%. Nevro’s revenue was up 38.9% on a year-over-year basis. During the same period last year, the firm posted ($0.34) earnings per share.
In related news, CFO Andrew H. Galligan sold 7,000 shares of Nevro stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $80.10, for a total value of $560,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wilfred E. Jaeger sold 160,542 shares of Nevro stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $80.77, for a total transaction of $12,966,977.34. Following the completion of the transaction, the director now owns 1,518 shares of the company’s stock, valued at approximately $122,608.86. The disclosure for this sale can be found here. Insiders sold 234,116 shares of company stock valued at $18,913,822 in the last 90 days. Company insiders own 9.10% of the company’s stock.
Several hedge funds have recently made changes to their positions in NVRO. New York State Common Retirement Fund grew its holdings in shares of Nevro by 13.2% in the third quarter. New York State Common Retirement Fund now owns 118,249 shares of the medical equipment provider’s stock valued at $10,746,000 after purchasing an additional 13,754 shares in the last quarter. Rhumbline Advisers grew its holdings in Nevro by 5.5% during the 3rd quarter. Rhumbline Advisers now owns 33,235 shares of the medical equipment provider’s stock worth $3,020,000 after acquiring an additional 1,744 shares in the last quarter. American International Group Inc. grew its holdings in Nevro by 8.1% during the 3rd quarter. American International Group Inc. now owns 18,579 shares of the medical equipment provider’s stock worth $1,688,000 after acquiring an additional 1,389 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Nevro by 22.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 130,642 shares of the medical equipment provider’s stock worth $11,873,000 after acquiring an additional 24,044 shares in the last quarter. Finally, Royce & Associates LP grew its holdings in Nevro by 71.4% during the 3rd quarter. Royce & Associates LP now owns 24,000 shares of the medical equipment provider’s stock worth $2,181,000 after acquiring an additional 10,000 shares in the last quarter.
Nevro stock opened at $86.52 on Friday. Nevro has a 1 year low of $65.00 and a 1 year high of $97.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect Nevro Corp (NVRO) Will Post Earnings of -$0.34 Per Share” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3343229/zacks-analysts-expect-nevro-corp-nvro-will-post-earnings-of-0-34-per-share.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.